LILIA SANTAMARIA-CANO: Open Payments
NPI 1841670528 · GOODYEAR, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,507 in 75 payments from 16 companies in 2025. Trend: 2023 $1,366 · 2024 $1,844 · 2025 $1,507
Food & beverage: $1,507
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $259 |
| GlaxoSmithKline, LLC. | 12 | $208 |
| ABBVIE INC. | 13 | $200 |
| Lilly USA, LLC | 12 | $156 |
| Astellas Pharma US Inc | 4 | $128 |
| Corcept Therapeutics | 4 | $106 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $105 |
| Abbott Laboratories | 3 | $72 |
| Novo Nordisk Inc | 3 | $65 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $57 |
Products named: TRELEGY ELLIPTA, FARXIGA, UBRELVY, Veozah, MOUNJARO, Korlym, XIFAXAN, FREESTYLE LIBRE 3.
Industry payments across AZ — which companies pay providers there.
